Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D. A. Eichenauer1, A. Engert1, M. Andre2, M. Federico3, T. Illidge4, M. Hutchings5, & M. Ladetto6 on behalf of the ESMO Guidelines Working Group* First Department of Internal Medicine, University Hospital Cologne and German Hodgkin Study Group (GHSG), Cologne, Germany; CHU Dinant-Godinne, UCL Namur, Yvoir, Belgium; Department of Oncology, Hematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy; Institute of Cancer Sciences, University of Manchester, Manchester, UK; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

[1]  A. Zelenetz,et al.  Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. , 2012, Blood.

[2]  A. Rossi,et al.  ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. , 2011, The New England journal of medicine.

[3]  A. Zelenetz,et al.  Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. , 2010, Blood.

[4]  R. Greil,et al.  Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial , 2010 .

[5]  H. Eich,et al.  Assessment of Residual Bulky Tumor Using FDG-PET In Patients with Advanced-Stage Hodgkin Lymphoma After Completion of Chemotherapy: Final Report of the GHSG HD15 Trial , 2010 .

[6]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[7]  R. Greil,et al.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Greil,et al.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[9]  R. Gascoyne,et al.  Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Coiffier,et al.  Nodular, lymphocyte‐predominant Hodgkin lymphoma , 2010, Cancer.

[11]  D. Niedzwiecki,et al.  Long-term follow-up of survival in Hodgkin's lymphoma. , 2009, The New England journal of medicine.

[12]  V. Diehl,et al.  Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Angrilli,et al.  ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  N. Schmitz,et al.  Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome , 2009, Haematologica.

[15]  G. Salles,et al.  Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Amthauer,et al.  Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. , 2008, Blood.

[17]  R. Müller,et al.  Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Schmitz,et al.  Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  V. Diehl,et al.  Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). , 2008, Blood.

[20]  J. Raemaekers,et al.  Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. , 2007, The New England journal of medicine.

[21]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  H. Eich,et al.  Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  V. Diehl,et al.  Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Santoro,et al.  Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. , 2007, Haematologica.

[26]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[27]  H. Eich,et al.  Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  C. Craddock,et al.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation , 2005, The Lancet.

[29]  H. Eich,et al.  Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Eich,et al.  A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Y. Natkunam,et al.  Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. , 2003, Blood.

[32]  V. Diehl,et al.  Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Dirk Hasenclever,et al.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.

[34]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  A. Zelenetz,et al.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. , 2001, Blood.

[36]  V. Diehl,et al.  Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.